FDA Approves Xeloda/Taxotere Combination for Advanced Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

ROCKVILLE, Maryland-The Food and Drug Administration (FDA) has approved a combination of the cancer drugs Xeloda (capecitabine) and Taxotere (docetaxel) for treating patients with metastatic breast cancer whose cancer has progressed after treatment with an anthracycline-containing chemotherapy regimen.

ROCKVILLE, Maryland—The Food and Drug Administration (FDA) has approved a combination of the cancer drugs Xeloda (capecitabine) and Taxotere (docetaxel) for treating patients with metastatic breast cancer whose cancer has progressed after treatment with an anthracycline-containing chemotherapy regimen.

Capecitabine, an oral cancer therapy, was initially approved as monotherapy for refractory metastatic breast cancer in 1998, the same year that docetaxel received approval for use in advanced breast cancer.

The approval of the combination was based on an open-label study of capecitabine in combination with docetaxel, compared with docetaxel alone conducted in 511 patients.

The study showed an improvement in response rates, time to worsening of disease, and survival in patients treated with the combination regimen. 

Related Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content